23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Vaxcyte, Inc. › 2025-2026

Vaxcyte, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Vaxcyte, Inc.’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 349Asset managers, any item
  • 2,507Fund votes
  • June 15, 2026Meeting date

Results at a glance

Meeting of June 15, 2026: 5 items on Vaxcyte, Inc.’s Form 8-K, filed June 16, 2026: 2 approved · 3 passed (calculated).

Dissent

Notable dissent: 2 directors (13.8%, 12.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13F, 7.2%, as of September 30, 2026) · Caligan Partners (13F, 1.4%, as of September 30, 2026)

Explore Vaxcyte, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Vaxcyte, Inc.

These tallies are Vaxcyte, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Vaxcyte, Inc. — official shareholder meeting results, meeting held June 15, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Olivier Brandicourt, M.D. 116,370,183---- 16,643,8974,354,403 87%Passed (calculated)—
Elect Director: Halley Gilbert, J.D. 114,704,274---- 18,309,8064,354,403 86%Passed (calculated)—
Elect Director: Grant Pickering, M.B.A. 132,112,840---- 901,2404,354,403 99.3%Passed (calculated)—
2. The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 137,230,032137,589862 ---- 99.9%Approved—
3. The approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers 130,011,0172,755,868247,195 --4,354,403 98%Approved—

Source: Vaxcyte, Inc., Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.

How asset managers voted at the Vaxcyte, Inc. 2025-2026 meeting

349 asset managers disclosed a vote on at least one Vaxcyte, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Olivier Brandicourt, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 7 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 116,370,183WITHHELD: 16,643,897
Details: description as filed, official tally, votes by 93 asset managers

Description as filed by funds: Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Olivier Brandicourt, M.D.

Vaxcyte, Inc.’s own tally for this item (“Elect Director: Olivier Brandicourt, M.D.”): 116,370,183 for, 16,643,897 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 67,002,205 for, 2,323,684 withheld, 1,104,841 abstained.

FOR
FOR: 67,002,205ABSTAIN: 1,104,841WITHHOLD: 2,323,684
Largest asset managers voting on “Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until t” at Vaxcyte, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity16,758,8510 01,200For
Vanguard15,629,4650 340For
JANUS INVESTMENT FUND8,778,7000 0130,463For
T. Rowe Price7,896,1780 00For
BlackRock5,381,9690 00For
State Street1,686,3640 016,237For
Charles Schwab1,403,4380 00For
MUTUAL FUND SERIES TRUST1,367,7530 00For
Jackson National939,3280 132,0690Mixed
Capital Group912,6880 00For
Prudential/PGIM836,4710 0540For
HARBOR FUNDS00 811,8950Abstain
JPMorgan573,6380 00For
Federated Hermes538,0850 00For
Victory Capital5670 0484,972Withhold
Equitable376,1880 092,529Mixed
JANUS ASPEN SERIES339,8890 00For
American Century00 0277,976Withhold
TIAA261,8210 00For
ALGER FUNDS00 0256,531Withhold
Bridge Builder Trust248,3080 00For
Hartford238,4180 00For
AIG/SunAmerica00 0228,519Withhold
John Hancock135,1080 92,9470Mixed
Voya223,2250 00For

Showing the 25 largest of 93 asset managers. All 93 are in the interactive database (link above).

Elect Director: Halley Gilbert, J.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 9 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%
FOR: 114,704,274WITHHELD: 18,309,806
Details: description as filed, official tally, votes by 93 asset managers

Description as filed by funds: Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Halley Gilbert, J.D.

Vaxcyte, Inc.’s own tally for this item (“Elect Director: Halley Gilbert, J.D.”): 114,704,274 for, 18,309,806 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 66,704,694 for, 2,621,194 withheld, 1,104,842 abstained.

FOR
FOR: 66,704,694ABSTAIN: 1,104,842WITHHOLD: 2,621,194
Largest asset managers voting on “Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until t” at Vaxcyte, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity16,758,8510 01,200For
Vanguard15,622,3930 357,071For
JANUS INVESTMENT FUND8,778,7000 0130,463For
T. Rowe Price7,896,1780 00For
BlackRock5,381,9690 00For
State Street1,686,3640 016,237For
Charles Schwab1,403,4380 00For
MUTUAL FUND SERIES TRUST1,367,7530 00For
Jackson National939,3280 132,0690Mixed
Capital Group912,6880 00For
Prudential/PGIM836,4710 0540For
HARBOR FUNDS00 811,8950Abstain
JPMorgan573,6380 00For
Federated Hermes538,0850 00For
Victory Capital5670 0484,972Withhold
Equitable376,1880 092,529Mixed
JANUS ASPEN SERIES339,8890 00For
American Century00 0277,976Withhold
TIAA261,8210 00For
ALGER FUNDS00 0256,531Withhold
Bridge Builder Trust248,3080 00For
Hartford238,4180 00For
AIG/SunAmerica00 0228,519Withhold
John Hancock135,1080 92,9470Mixed
Voya00 0223,225Withhold

Showing the 25 largest of 93 asset managers. All 93 are in the interactive database (link above).

Elect Director: Grant Pickering, M.B.A.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 9 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 132,112,840WITHHELD: 901,240
Details: description as filed, official tally, votes by 93 asset managers

Description as filed by funds: Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Grant E. Pickering, M.B.A.

Vaxcyte, Inc.’s own tally for this item (“Elect Director: Grant Pickering, M.B.A.”): 132,112,840 for, 901,240 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 70,113,523 for, 237,590 withheld, 79,617 abstained.

FOR
FOR: 70,113,523ABSTAIN: 79,617WITHHOLD: 237,590
Largest asset managers voting on “Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until t” at Vaxcyte, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity16,760,0510 00For
Vanguard15,629,4970 20For
JANUS INVESTMENT FUND8,909,1630 00For
T. Rowe Price7,896,1780 00For
BlackRock5,381,9690 00For
State Street1,702,6010 00For
Charles Schwab1,403,4380 00For
MUTUAL FUND SERIES TRUST1,367,7530 00For
Jackson National1,053,2520 18,1450For
Capital Group912,6880 00For
Prudential/PGIM836,4710 0540For
HARBOR FUNDS811,8950 00For
JPMorgan573,6380 00For
Federated Hermes538,0850 00For
Victory Capital485,5390 00For
Equitable376,1880 092,529Mixed
JANUS ASPEN SERIES339,8890 00For
American Century277,9760 00For
TIAA261,8210 00For
ALGER FUNDS256,5310 00For
Bridge Builder Trust248,3080 00For
Hartford238,4180 00For
AIG/SunAmerica228,5190 00For
John Hancock166,5850 61,4700Mixed
Voya223,2250 00For

Showing the 25 largest of 93 asset managers. All 93 are in the interactive database (link above).

The approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 11 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 130,011,017AGAINST: 2,755,868

Prior year: 63.7% for (June 12, 2025 meeting) ▲ 34.2 pts

Details: description as filed, official tally, votes by 347 asset managers

Description as filed by funds: Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.

Vaxcyte, Inc.’s own tally for this item (“3. The approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers”): 130,011,017 for, 2,755,868 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The approval of the non-binding resolution on named executive officer compensation was approved by the votes indicated:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Vaxcyte, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, 54 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 92 asset managers voting on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.” at Vaxcyte, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity16,760,0510 00For
Vanguard15,610,49918,999 00For
JANUS INVESTMENT FUND8,909,1630 00For
T. Rowe Price7,791,173105,005 00For
BlackRock5,381,9690 00For
State Street1,700,4992,102 00For
Charles Schwab1,403,4380 00For
MUTUAL FUND SERIES TRUST1,367,7530 00For
Jackson National1,071,3970 00For
Capital Group0912,688 00Against
Prudential/PGIM832,1114,900 00For
HARBOR FUNDS811,8950 00For
JPMorgan573,6380 00For
Federated Hermes538,0850 00For
Victory Capital485,5390 00For
Equitable468,7170 00For
JANUS ASPEN SERIES339,8890 00For
American Century277,9760 00For
TIAA261,8210 00For
ALGER FUNDS256,5310 00For
Bridge Builder Trust248,3080 00For
Hartford238,4180 00For
AIG/SunAmerica228,5190 00For
John Hancock228,0550 00For
Voya223,2250 00For

Fund voting reports, all 92 managers: 69,300,959 for, 1,128,836 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 284 asset managers voting on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.” at Vaxcyte, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson25,385,6900 00For
Fidelity16,805,5890 00For
T. Rowe Price12,679,694156,043 00For
RA CAPITAL MANAGEMENT, L.P.11,474,5990 00For
Wellington5,043,5160 00For
BlackRock4,421,7390 00For
State Street4,192,8702,553 00For
Deep Track Capital, LP4,080,2480 00For
WESTFIELD CAPITAL MANAGEMENT CO LP3,235,3810 00For
GEODE CAPITAL MANAGEMENT, LLC3,223,7170 00For
Polar Capital Holdings Plc2,692,4500 00For
Kynam Capital Management, LP00 01,975,153Withhold
Charles Schwab1,411,4950 00For
DE Shaw1,295,3120 00For
JENNISON ASSOCIATES LLC1,095,6894,606 00For
Vanguard1,065,8070 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.1,000,0000 00For
Northern Trust987,5780 00For
Aberdeen928,9330 00For
Capital Research Global Investors0912,688 00Against
Paradigm Biocapital Advisors LP829,6550 00For
Baupost800,0000 00For
Novo Holdings A/S800,0000 00For
Saturn V Capital Management LP754,0360 00For
Eversept Partners, LP747,1620 00For

Institutional-manager reports, all 284 managers: 115,842,800 for, 2,180,765 against, 1,975,153 withheld, 3,840 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting…

Official resultAUDIT-RELATEDReported outcome: Approved

99.9% Approved · of votes cast

FOR 99.9%
FOR: 137,230,032AGAINST: 137,589

Prior year: 99.8% for (June 12, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Vaxcyte, Inc.’s own tally for this item (“2. The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 137,230,032 for, 137,589 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The appointment was ratified by the votes indicated:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 70,430,834 for, 66 against.

FOR
FOR: 70,430,834AGAINST: 66
Largest asset managers voting on “Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accoun” at Vaxcyte, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity16,760,0510 00For
Vanguard15,629,4990 00For
JANUS INVESTMENT FUND8,909,1630 00For
T. Rowe Price7,896,1780 00For
BlackRock5,381,9690 00For
State Street1,702,53566 00For
Charles Schwab1,403,4380 00For
MUTUAL FUND SERIES TRUST1,367,7530 00For
Jackson National1,071,3970 00For
Capital Group912,6880 00For
Prudential/PGIM837,0110 00For
HARBOR FUNDS811,8950 00For
JPMorgan573,6380 00For
Federated Hermes538,0850 00For
Victory Capital485,5390 00For
Equitable468,7170 00For
JANUS ASPEN SERIES339,8890 00For
American Century277,9760 00For
TIAA261,8210 00For
ALGER FUNDS256,5310 00For
Bridge Builder Trust248,3080 00For
Hartford238,4180 00For
AIG/SunAmerica228,5190 00For
John Hancock228,0550 00For
Voya223,2250 00For

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

Largest Vaxcyte, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 144,397,682 shares outstanding at the time of that meeting.

Fund voting reports: top Vaxcyte, Inc. shareholders by shares voted on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 11.61%
2Vanguard 10.82%
3JANUS INVESTMENT FUND 6.17%
4T. Rowe Price 5.47%
5BlackRock 3.73%
6State Street 1.18%
7Charles Schwab 0.97%
8MUTUAL FUND SERIES TRUST 0.95%
9Jackson National 0.74%
10Capital Group 0.63%
Institutional-manager reports: top Vaxcyte, Inc. shareholders by shares voted on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named…”, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 17.58%
2Fidelity 11.64%
3T. Rowe Price 8.89%
4RA CAPITAL MANAGEMENT, L.P. 7.95%
5Wellington 3.49%
6BlackRock 3.06%
7State Street 2.91%
8Deep Track Capital, LP 2.83%
9WESTFIELD CAPITAL MANAGEMENT CO LP 2.24%
10GEODE CAPITAL MANAGEMENT, LLC 2.23%

Reported Vaxcyte, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Vaxcyte, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
JANUS HENDERSON GROUP PLC16,575,875 11.48%Schedule 13G, filed May 15, 2026
FMR (Fidelity)16,492,861 11.42%Form 13F, quarter ended March 31, 2026
FMR LLC13,132,825 9.09%Proxy statement (DEF 14A), table as of March 31, 2026
RA Capital Management, L.P.12,974,599 8.99%Schedule 13G, filed May 15, 2026
T. Rowe Price Investment Management, Inc.11,296,333 7.82%Schedule 13G, filed February 17, 2026
BlackRock10,971,816 7.60%Form 13F, quarter ended March 31, 2026
Wellington Management5,614,597 3.89%Form 13F, quarter ended March 31, 2026
State Street4,440,519 3.08%Form 13F, quarter ended March 31, 2026
D.E. Shaw2,865,318 1.98%Form 13F, quarter ended March 31, 2026
Grant E. Pickering2,205,945 1.53%Proxy statement (DEF 14A), table as of March 31, 2026

Percentages above are of 144,397,682 shares outstanding, as reported by Vaxcyte, Inc. on its Form 10-Q dated May 4, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Vaxcyte, Inc.'s shareholder meeting held June 15, 2026, in the 2025-2026 proxy season, 349 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,507 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding, advisory basis, of the compensation of the Company's named… — Vaxcyte, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Vaxcyte, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Vaxcyte, Inc.’s 10-Q dated May 4, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Vaxcyte, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Vaxcyte (PCVX) 2026 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/vaxcyte-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.